



US011318191B2

(12) United States Patent
Engelund et al.**(10) Patent No.: US 11,318,191 B2**
(45) Date of Patent: May 3, 2022**(54) GLP-1 COMPOSITIONS AND USES THEREOF****(71) Applicant: Novo Nordisk A/S, Bagsvaerd (DK)****(72) Inventors: Dorthe Kot Engelund, Holte (DK); Soeren Snitker, Holte (DK); Andrew Mark Louw, Vaerloese (DK)****(73) Assignee: Novo Nordisk A/S, Bagsvaerd (DK)****(*) Notice:** Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.**(21) Appl. No.: 17/177,438****(22) Filed: Feb. 17, 2021****(65) Prior Publication Data**

US 2021/0252111 A1 Aug. 19, 2021

(30) Foreign Application Priority Data

Feb. 18, 2020	(EP)	20157963
Apr. 24, 2020	(EP)	20171240
Jun. 17, 2020	(EP)	20180645
Jun. 18, 2020	(EP)	20180832
Jan. 4, 2021	(EP)	21150056
Jan. 11, 2021	(EP)	21151004
Feb. 2, 2021	(EP)	21154657

(51) Int. Cl.

A61K 38/26	(2006.01)
A61K 9/00	(2006.01)
A61K 47/02	(2006.01)
A61K 47/10	(2017.01)
A61K 47/22	(2006.01)

(52) U.S. Cl.CPC **A61K 38/26** (2013.01); **A61K 9/0019** (2013.01); **A61K 47/02** (2013.01); **A61K 47/10** (2013.01); **A61K 47/22** (2013.01)**(58) Field of Classification Search**CPC A61K 38/26
See application file for complete search history.**(56) References Cited**

U.S. PATENT DOCUMENTS

2,444,570 A	8/1946	Lawrence et al.
2,828,742 A	4/1958	Ashkenaz
3,318,289 A	5/1967	Marynissen
3,758,683 A	9/1973	Jackson
4,282,316 A	8/1981	Modrovich
4,425,346 A	1/1984	Horlington
4,468,346 A	8/1984	Paul et al.
4,470,317 A	9/1984	Sabloewski et al.
4,483,849 A	11/1984	Carter et al.
4,498,904 A	2/1985	Turner et al.
4,568,335 A	2/1986	Updike et al.
4,585,439 A	4/1986	Michel
4,592,745 A	6/1986	Rex et al.
4,629,455 A	12/1986	Kanno
4,833,379 A	5/1989	Kaibel et al.
4,865,591 A	9/1989	Sams
4,883,472 A	11/1989	Michel

4,917,685 A	4/1990	Viswanathan et al.
4,919,596 A	4/1990	Slate et al.
4,936,833 A	6/1990	Sams
4,973,318 A	11/1990	Holm et al.
4,994,033 A	2/1991	Shockey et al.
5,017,190 A	5/1991	Simon et al.
5,092,842 A	3/1992	Bechtold et al.
5,112,317 A	5/1992	Michel
5,114,406 A	5/1992	Gabriel et al.
5,118,666 A	6/1992	Habener
5,120,712 A	6/1992	Habener
5,169,759 A	12/1992	Faust et al.
5,169,771 A	12/1992	Christner et al.
5,206,216 A	4/1993	Yoshida
5,206,219 A	4/1993	Desai
5,207,752 A	5/1993	Sorenson et al.
5,216,011 A	6/1993	Paborji et al.
5,216,437 A	6/1993	Yamamoto et al.
5,226,895 A	7/1993	Harris
5,232,459 A	8/1993	Hjertman
5,232,706 A	8/1993	Palomo Coll
5,246,417 A	9/1993	Haak et al.
5,257,987 A	11/1993	Athayde et al.
5,271,527 A	12/1993	Haber et al.
5,272,135 A	12/1993	Takruri
5,279,585 A	1/1994	Balkwill
5,279,586 A	1/1994	Balkwill
5,281,198 A	1/1994	Haber et al.
5,284,480 A	2/1994	Porter et al.
5,304,152 A	4/1994	Sams
5,308,340 A	5/1994	Harris
5,314,412 A	5/1994	Rex

(Continued)

FOREIGN PATENT DOCUMENTS

AU	611385 B2	6/1991
CA	2223531 A1	12/1996

(Continued)

OTHER PUBLICATIONS

Yang et al., "The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model stroke", Aug. 2019, Neuropharmacology, vol. 158, No. 107748, pp. 1-14.

Doenicke et al. "Solvent for etomidate may cause pain and adverse effects." British journal of anaesthesia. Sep. 1999, vol. 83, No. 3, pp. 464-466.

Fransson et al., "Local Tolerance of Subcutaneous Injections," Journal of Pharm. Pharmacol., Oct. 1996, vol. 48, pp. 1012-1015. Niedermirtl et al., "Etomidate and propylene glycol activate nociceptive TRP ion channels." Molecular pain. Nov. 2018, vol. 14, p. 1-18. Chen, Juliette. "The Debate About Needle Reuse" <http://www.diabeteshealth.com/blog/the-debate-about-needle-reuse/> Accessed Jan. 9, 2015.

(Continued)

Primary Examiner — Gyan Chandra

(74) Attorney, Agent, or Firm — Rosemarie R. Wilk-Orescan

(57) ABSTRACT

The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.1% (w/w) phenol and above 6.4 mg/ml sodium chloride, their preparation, kits comprising such compositions as well as uses thereof.

26 Claims, 1 Drawing Sheet